{"id":11379,"date":"2011-10-26T00:00:00","date_gmt":"2011-10-25T22:00:00","guid":{"rendered":"https:\/\/idibell.cat\/es\/blog\/2011\/10\/26\/descubren-una-alteracion-epigenetica-en-cancer-de-mama-que-predice-la-falta-de-respuesta-a-determinados-tratamientos-de-quimioterapia\/"},"modified":"2020-05-26T09:36:54","modified_gmt":"2020-05-26T07:36:54","slug":"descubren-una-alteracion-epigenetica-en-cancer-de-mama-que-predice-la-falta-de-respuesta-a-determinados-tratamientos-de-quimioterapia","status":"publish","type":"post","link":"https:\/\/idibell.cat\/es\/2011\/10\/descubren-una-alteracion-epigenetica-en-cancer-de-mama-que-predice-la-falta-de-respuesta-a-determinados-tratamientos-de-quimioterapia\/","title":{"rendered":"Descubren una alteraci\u00f3n epigen\u00e9tica en c\u00e1ncer de mama que predice la falta de respuesta a determinados tratamientos de quimioterapia"},"content":{"rendered":"


El estudio ha sido coordinado por investigadores del Netherlands Cancer Institute<\/span><\/a>. Los resultados de esta investigaci\u00f3n se publican en el \u00faltimo n\u00famero de la revista Nature Communications<\/span><\/a><\/em>.
La prote\u00edna p53 denominada guardi\u00e1n del genoma se encarga de eliminar las c\u00e9lulas premalignas. Los investigadores han descubierto que la RBM38 le ayuda a ejercer esta defensa mediante el control de unas peque\u00f1as mol\u00e9culas reguladoras denominadas microARNs. El
investigador del IDIBELL Manel Esteller ha explicado que \u201cesta funci\u00f3n normal de RBM38 que har\u00eda desaparecer las c\u00e9lulas con defectos susceptibles de originar un tumor se pierde en el c\u00e1ncer de mama\u201d.
El estudio concluye que los tumores mamarios desactivan epigen\u00e9ticamente el gen de RBM38 (se produce una alteraci\u00f3n qu\u00edmica en el ADN del gen que codifica por esta prote\u00edna), de forma que no puede interactuar entre p53 y los microARns para evitar el crecimiento an\u00f3malo. \u201cSer\u00eda como una misi\u00f3n de paz de la ONU fracasada\u201d ha explicado Esteller.
Aplicaci\u00f3n pr\u00e1ctica <\/strong>
<\/strong> Seg\u00fan Manel Esteller, este hallazgo, adem\u00e1s de profundizar en el conocimiento de los or\u00edgenes del c\u00e1ncer, tambi\u00e9n podr\u00eda tener una aplicaci\u00f3n pr\u00e1ctica. \u201cLos tumores de mama en los que no funciona la prote\u00edna RBM38 son especialmente resistencia a determinadas quimioterapias, como las que contienen el f\u00e1rmaco doxorubicina. Por lo tanto podr\u00eda ayudar a seleccionar en estos pacientes un tratamiento con otro f\u00e1rmaco para maximizar las probabilidades de que los pacientes respondan a la terapia\u201d.
Referencia del art\u00edculo <\/strong>
<\/strong>
<\/strong>Nicolas L\u00e9veill\u00e9, Ran Elkon, Veronica Davalos*, Vijayalaxmi Manoharan, Dave Hollingworth, Joachim Oude Vrielink, Carlos le Sage, Carlos A. Melo, Hugo M. Horlings, Jelle Wesseling, Jernej Ule, Manel Esteller*, Andres Ramos & Reuven Agami.Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity. Nature Communications 2:513. doi: 10.1038\/ncomms1519.
*Investigadores del IDIBELL<\/p>\n","protected":false},"excerpt":{"rendered":"

Investigadores del IDIBELL han colaborado en un estudio caracteriza una prote\u00edna denominada RBM38, clave en la regulaci\u00f3n de la muerte de las c\u00e9lulas tumorales, que se desactiva en los tumores mamarios, haci\u00e9ndolos m\u00e1s resistentes a determinados tratamientos de quimioterapia. Aplicaci\u00f3n pr\u00e1ctica Referencia del art\u00edculo<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[286],"tags":[],"class_list":["post-11379","post","type-post","status-publish","format-standard","hentry","category-epigenetica-del-cancer-cancer"],"publishpress_future_action":{"enabled":false,"date":"2025-04-11 00:18:17","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11379","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=11379"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/11379\/revisions"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=11379"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=11379"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=11379"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}